Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]

Shen J, Goodkin ML, Tong W, Attar M. Clin Ophthalmol. 2017;11:1761–1767.On page 1765, Clinical correlation with evidence for use of bimatoprost twice daily in humans section, second column, last line, “−5.4 to −5.6 mm Hg” should have read “...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shen J, Goodkin ML, Tong W, Attar M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f26af62ff30e45c68a26c5003e44a6dd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f26af62ff30e45c68a26c5003e44a6dd
record_format	dspace
spelling	oai:doaj.org-article:f26af62ff30e45c68a26c5003e44a6dd2021-12-02T05:24:53ZOcular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]1177-5483https://doaj.org/article/f26af62ff30e45c68a26c5003e44a6dd2018-08-01T00:00:00Zhttps://www.dovepress.com/corrigendum-ocular-pharmacokinetics-and-tolerability-of-bimatopro-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Shen J, Goodkin ML, Tong W, Attar M. Clin Ophthalmol. 2017;11:1761–1767.On page 1765, Clinical correlation with evidence for use of bimatoprost twice daily in humans section, second column, last line, “−5.4 to −5.6 mm Hg” should have read “−5.4 to −6.0 mm Hg”.Read the original articleShen JGoodkin MLTong WAttar MDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 1471-1472 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Shen J Goodkin ML Tong W Attar M Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
description	Shen J, Goodkin ML, Tong W, Attar M. Clin Ophthalmol. 2017;11:1761–1767.On page 1765, Clinical correlation with evidence for use of bimatoprost twice daily in humans section, second column, last line, “−5.4 to −5.6 mm Hg” should have read “−5.4 to −6.0 mm Hg”.Read the original article
format	article
author	Shen J Goodkin ML Tong W Attar M
author_facet	Shen J Goodkin ML Tong W Attar M
author_sort	Shen J
title	Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
title_short	Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
title_full	Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
title_fullStr	Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
title_full_unstemmed	Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
title_sort	ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [corrigendum]
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/f26af62ff30e45c68a26c5003e44a6dd
work_keys_str_mv	AT shenj ocularpharmacokineticsandtolerabilityofbimatoprostophthalmicsolutionsadministeredonceortwicedailyinrabbitsandclinicaldosingimplicationscorrigendum AT goodkinml ocularpharmacokineticsandtolerabilityofbimatoprostophthalmicsolutionsadministeredonceortwicedailyinrabbitsandclinicaldosingimplicationscorrigendum AT tongw ocularpharmacokineticsandtolerabilityofbimatoprostophthalmicsolutionsadministeredonceortwicedailyinrabbitsandclinicaldosingimplicationscorrigendum AT attarm ocularpharmacokineticsandtolerabilityofbimatoprostophthalmicsolutionsadministeredonceortwicedailyinrabbitsandclinicaldosingimplicationscorrigendum
_version_	1718400447918637056

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]

Ejemplares similares